Fresenius Kabi
Bruce Shackelford is a seasoned professional in the pharmaceutical and biotechnology sectors, currently serving as the Technology Transfer and Validation Manager at Fresenius Kabi since January 2021. Prior experience includes the role of Validation Manager at Thermo Fisher Scientific, where responsibilities encompassed managing revalidation programs, temperature mapping, and computer automation, as well as overseeing sterilization and continuous manufacturing processes. Bruce also held the position of Sr. Manager Operations at Patheon, leading a team of 250 employees in terminal sterilization and packaging operations. Earlier in his career, Bruce served as Validation Manager at DSM, focusing on cleaning validation, solid dosage forms, and packaging. Bruce earned a Bachelor of Science in Biochemistry from East Carolina University between 1980 and 1984.
This person is not in any teams
This person is not in any offices
Fresenius Kabi
16 followers
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.